Tip Card: Darzalex/Darzalex Faspro

Darzalex® (daratumumab) is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells. The original formulation of Darzalex is administered as an intravenous infusion, and the FDA has also approved Darzalex Faspro® (daratumumab + hyaluronidase-fihj) as a subcutaneous injection. Both formulations are available as monotherapy and as part of combination therapies.